Trial
NCT04455958
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Lopinavir/Ritonavir
Why stopped
limited resources
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-26